These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 25124163)
21. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. Kothari N; Teer JK; Abbott AM; Srikumar T; Zhang Y; Yoder SJ; Brohl AS; Kim RD; Reed DR; Shibata D Cancer; 2016 Sep; 122(18):2828-35. PubMed ID: 27244218 [TBL] [Abstract][Full Text] [Related]
22. Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene. Hino H; Shiomi A; Kusuhara M; Kagawa H; Yamakawa Y; Hatakeyama K; Kawabata T; Oishi T; Urakami K; Nagashima T; Kinugasa Y; Yamaguchi K Cancer Med; 2019 Aug; 8(10):4587-4597. PubMed ID: 31240875 [TBL] [Abstract][Full Text] [Related]
23. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867 [TBL] [Abstract][Full Text] [Related]
24. Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data. Jiang M; Jia Y; Han J; Shi J; Su C; Zhang R; Xing M; Jin S; Zong H Front Genet; 2022; 13():963964. PubMed ID: 36479248 [No Abstract] [Full Text] [Related]
25. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181 [TBL] [Abstract][Full Text] [Related]
26. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063 [TBL] [Abstract][Full Text] [Related]
27. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation. Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678 [TBL] [Abstract][Full Text] [Related]
28. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778 [TBL] [Abstract][Full Text] [Related]
29. High prevalence of "non-pathogenic" POLE mutation with poor prognosis in a cohort of endometrial cancer from South India. Kuriakose S; Dhanasooraj D; Shiny PM; Shammy S; Sona VP; Manjula AA; Ramachandran A; Vijaykumar B; Susan N; Dinesan M; Sankar UV; Ramachandran K; Sreedharan PS Int J Gynaecol Obstet; 2024 Sep; 166(3):1263-1272. PubMed ID: 38571325 [TBL] [Abstract][Full Text] [Related]
30. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a Gong J; Wang C; Lee PP; Chu P; Fakih M J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185 [TBL] [Abstract][Full Text] [Related]
31. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer. Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149 [TBL] [Abstract][Full Text] [Related]
32. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062 [TBL] [Abstract][Full Text] [Related]
33. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer. Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883 [TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability. Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874 [TBL] [Abstract][Full Text] [Related]
35. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916 [TBL] [Abstract][Full Text] [Related]
36. Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies. Phipps AI; Alwers E; Harrison T; Banbury B; Brenner H; Campbell PT; Chang-Claude J; Buchanan D; Chan AT; Farris AB; Figueiredo JC; Gallinger S; Giles GG; Jenkins M; Milne RL; Newcomb PA; Slattery ML; Song M; Ogino S; Zaidi SH; Hoffmeister M; Peters U Gastroenterology; 2020 Jun; 158(8):2158-2168.e4. PubMed ID: 32088204 [TBL] [Abstract][Full Text] [Related]
37. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS. Alwers E; Bläker H; Walter V; Jansen L; Kloor M; Arnold A; Sieber-Frank J; Herpel E; Tagscherer KE; Roth W; Chang-Claude J; Brenner H; Hoffmeister M BMC Cancer; 2019 Jul; 19(1):681. PubMed ID: 31296182 [TBL] [Abstract][Full Text] [Related]
38. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1. Buchanan DD; Stewart JR; Clendenning M; Rosty C; Mahmood K; Pope BJ; Jenkins MA; Hopper JL; Southey MC; Macrae FA; Winship IM; Win AK Genet Med; 2018 Aug; 20(8):890-895. PubMed ID: 29120461 [TBL] [Abstract][Full Text] [Related]
39. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. Domingo E; Camps C; Kaisaki PJ; Parsons MJ; Mouradov D; Pentony MM; Makino S; Palmieri M; Ward RL; Hawkins NJ; Gibbs P; Askautrud H; Oukrif D; Wang H; Wood J; Tomlinson E; Bark Y; Kaur K; Johnstone EC; Palles C; Church DN; Novelli M; Danielsen HE; Sherlock J; Kerr D; Kerr R; Sieber O; Taylor JC; Tomlinson I Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):635-643. PubMed ID: 30042065 [TBL] [Abstract][Full Text] [Related]
40. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis. Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]